From the Journals

Metformin and AMD: Signal or Noise?

Five-year population study details 37% lower incidence of intermediate AMD in type 2 diabetic patients prescribed metformin

  • March 18, 2026

  • 3 min

Share

A population-based study found that metformin use is associated with a 37% lower incidence of intermediate age-related macular degeneration (AMD) over five years in patients with type 2 diabetes. The study, part of the ISDR program in Liverpool, involved 2,089 patients screened in 2011, who primarily displayed no AMD at baseline. With rigorous image grading compared to prior studies, the research suggests metformin may offer protective effects against AMD’s intermediate stage, corroborating its antioxidant and anti-inflammatory properties, while noting observational limitations in establishing causality.

Original Source(s)

Metformin and AMD: Signal or Noise?

  • March 18, 2026

Related Content

Ophthalmology’s Role in the Opioid Crisis

Retrospective cohort study investigates how ophthalmologists can provide potentially life-saving care to substance use disorder patients

Red Eye, Global Challenge

Narrative review calls for clearer guidance on noninfectious conjunctival hyperemia

  • March 18, 2026

  • 2 min
Scaling Diabetic Eye Care in Vietnam

Orbis and Roche launch major diabetic eye care initiative in the country

  • March 17, 2026

  • 2 min